Amanta Healthcare IPO Day 3 Review: Should You Apply?

Amanta Healthcare, a notable name in the pharmaceutical and healthcare sector, launched its IPO recently, attracting attention from both retail and institutional investors. With the offer now in its third day, many prospective investors are eager to understand how the issue is performing in the market. The IPO’s grey market premium (GMP)-a key indicator of investor sentiment outside official channels—along with subscription numbers, provides useful insights into demand and potential listing gains. However, investing in IPOs requires careful analysis beyond just these metrics. This article takes you through the latest status of the Amanta Healthcare IPO on day 3, explains what the GMP and subscription data suggest, and helps you decide whether applying for the IPO aligns with your investment goals.

Understanding the Grey Market Premium (GMP)

The grey market premium represents the unofficial price at which IPO shares are bought and sold before the stock lists on the exchange. It serves as a real-time sentiment gauge among investors. For Amanta Healthcare, the GMP has shown moderate fluctuations during the first three days. Initially, the premium was slightly positive, signaling optimism about the stock's potential gains. However, recent days have seen the GMP stabilize, reflecting cautious investor sentiment. A stable or rising GMP often suggests strong demand and anticipation of a good listing, while a declining GMP may signal concerns about valuation or market conditions. For investors considering applying, the current GMP indicates balanced expectations-neither overly enthusiastic nor pessimistic.

Subscription Status : What the Numbers Show

The subscription data for Amanta Healthcare’s IPO offers additional clues about demand. As of day 3, the IPO has garnered a moderate subscription level across retail, institutional, and non-institutional categories. Retail investor participation remains steady, showing confidence in the company’s growth story and sector prospects. Qualified institutional buyers (QIBs) have shown interest but are yet to fully subscribe, which is not unusual midway through the IPO period. The non-institutional segment is also steady, reflecting measured enthusiasm. Investors should watch the final subscription numbers closely, as oversubscription often leads to allotments by lottery, while undersubscription may imply easier access but a higher risk at listing.

Should You Apply for the Amanta Healthcare IPO?

Deciding whether to apply for the IPO depends on several factors. First, the company’s fundamentals and future growth prospects matter. Amanta Healthcare operates in a resilient sector with steady demand for pharmaceutical products, which is a positive sign. The IPO pricing also appears reasonable compared to peers, making it attractive for long-term investors. However, IPO investments carry risks, including market volatility and uncertainties around listing-day performance. The current GMP and subscription data suggest balanced market sentiment, so investors should weigh their risk tolerance, investment horizon, and portfolio goals. If you are comfortable with short-term price fluctuations and believe in the company’s growth story, applying could be worthwhile. Conversely, if you prefer safer or more established investments, waiting until after the listing to buy might be the better option.